Abstract
The publication of the Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies study [ARBITER 6-HALTS (ClinicalTrials.gov number, NCT00397657)] adds fuel to a controversy regarding the issue of combination therapy with ezetimibe in the prevention of cholesterol-related atherogenic disease [Taylor et al. 2009]. Patients who were at high risk for atherosclerotic vascular disease and receiving statin treatment were randomized to adjunctive therapy with either ezetimibe or niacin over a 14 month period. Progression of atherosclerosis was judged from changes in common carotid artery intima-media thickness.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
